Table 5.

Distribution of different karyotypic risk categories and Flt3-ITD mutations among groups of AML patients

nFlt3-ITD, no.Risk karyotype, no.
Favorable5-150Unfavorable5-151Intermediate/unknown5-152
Group I,EVI1+ andMDS1-EVI1 
Group II, EVI1+ andMDS1-EVI1+ 26 12 14 
Group III, EVI1 andMDS1-EVI1+ 12 
Group IV, EVI1 andMDS1-EVI1 275 82 53 33 189 
nFlt3-ITD, no.Risk karyotype, no.
Favorable5-150Unfavorable5-151Intermediate/unknown5-152
Group I,EVI1+ andMDS1-EVI1 
Group II, EVI1+ andMDS1-EVI1+ 26 12 14 
Group III, EVI1 andMDS1-EVI1+ 12 
Group IV, EVI1 andMDS1-EVI1 275 82 53 33 189 
F5-150

t(8;21), t(15;17) or inv(16).

F5-151

−7/7q-, −5/5q-, t(9;22), t(6;9) or complex karyotype (>3 abnormalities).

F5-152

Other cytogenetic aberrations or normal karyotype.

Close Modal

or Create an Account

Close Modal
Close Modal